T1	Participants 478 653	Consecutive post-menopausal women aged 50 years to 86 years starting treatment with raloxifene according to daily practice were enrolled from 126 primary care offices in Spain
T2	Participants 659 698	women were assigned to two study groups
T3	Participants 700 707	Group A
T4	Participants 785 794	group B f
T5	Participants 942 967	745 post-menopausal women
T6	Participants 1070 1087	both study groups
T7	Participants 1165 1179	groups A and B
T8	Participants 1413 1427	groups A and B
T9	Participants 1470 1481	both groups
